The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

 
Web www.patentalert.com

< Controlled release fertilizer material and process for production thereof

< LPS-responsive chs1/beige-like anchor gene and therapeutic applications thereof

> Chimeric human T1R3 taste receptor polypeptides and compositions containing same

> Luminous bacteria and methods for the isolation, identification and quantitation of toxicants
~ 00607